These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6604543)

  • 1. Phenotypic conversion of acute leukaemia from T-lymphoblastic to myeloblastic induced by therapy with 2'-deoxycoformycin.
    Murphy SB; Stass S; Kalwinsky D; Rivera G
    Br J Haematol; 1983 Oct; 55(2):285-93. PubMed ID: 6604543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
    Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Mitchell BS; Koller CA; Kelley WN
    Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical, pharmacologic, and immunologic effects of 2'-deoxycoformycin.
    Cummings FJ; Crabtree GW; Wiemann MC; Spremulli EN; Parks RE; Calabresi P
    Clin Pharmacol Ther; 1988 Nov; 44(5):501-9. PubMed ID: 3263248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose deoxycoformycin in lymphoid malignancy.
    Grever MR; Leiby JM; Kraut EH; Wilson HE; Neidhart JA; Wall RL; Balcerzak SP
    J Clin Oncol; 1985 Sep; 3(9):1196-201. PubMed ID: 2993534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
    Prentice HG; Russell NH; Lee N; Ganeshaguru K; Blacklock H; Piga A; Smyth JF; Hoffbrand AV
    Lancet; 1981 Dec; 2(8258):1250-4. PubMed ID: 6118669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of deoxycoformycin.
    Major PP; Agarwal RP; Kufe DW
    Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
    Kefford RF; Fox RM
    Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of adenosine deaminase leads to enhanced antibody responses in the mouse.
    Nicholson JK; Gordon DS; McDougal JS
    Cell Immunol; 1983 Jul; 79(2):320-33. PubMed ID: 6347398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
    Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
    Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transport of deoxycoformycin in human erythrocytes. Measurement by adenosine deaminase titration and radioisotope assays.
    Chen SF; Stoeckler JD; Parks RE
    Biochem Pharmacol; 1984 Dec; 33(24):4069-79. PubMed ID: 6334522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of DNA strand breaks in chronic lymphocytic leukemia following treatment with 2'-deoxycoformycin in vivo and in vitro.
    Begleiter A; Glazer RI; Israels LG; Pugh L; Johnston JB
    Cancer Res; 1987 May; 47(9):2498-503. PubMed ID: 3494509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro--lack of correlation with clinical response.
    Ho AD; Ganeshaguru K; Knauf W; Dietz G; Trede I; Hoffbrand AV; Hunstein W
    Leuk Res; 1989; 13(4):269-78. PubMed ID: 2785618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.
    Dillman RO; Mick R; McIntyre OR
    J Clin Oncol; 1989 Apr; 7(4):433-8. PubMed ID: 2784491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
    Agarwal RP
    Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
    [No Abstract]   [Full Text] [Related]  

  • 18. Biochemical consequences of adenosine deaminase inhibition in vivo. Differential effects in acute and chronic T cell leukemia.
    Mitchell BS; Sidi Y; Hershfield M; Koller CA
    Ann N Y Acad Sci; 1985; 451():129-37. PubMed ID: 3878114
    [No Abstract]   [Full Text] [Related]  

  • 19. Deoxycoformycin in the treatment of leukemias and lymphomas.
    Smyth JF; Prentice HG; Proctor S; Hoffbrand AV
    Ann N Y Acad Sci; 1985; 451():123-8. PubMed ID: 3878113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition.
    Koller CA; Mitchell BS; Grever MR; Mejias E; Malspeis L; Metz EN
    Cancer Treat Rep; 1979; 63(11-12):1949-52. PubMed ID: 316725
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.